ACT Brief: CRO Partnership in Program Recruitment, Psychedelic Trial Design Guidance, and Breast Cancer Pathway Inhibitor

In today's ACT Brief, we examine CRO success through program-level partnership, FDA guidance addressing psychedelic trial design challenges, and approval of a comprehensive cancer pathway inhibitor.